Concise summaries of everything published in the latest weekly issue of the New England Journal of Medicine (NEJM). NEJM publishes new medical research findings, review articles, and editorial opinion on topics of importance to biomedical science and clinical practice.
…
continue reading
Indhold leveret af ReachMD. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af ReachMD eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
Manage episode 455848953 series 3128163
Indhold leveret af ReachMD. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af ReachMD eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
CME credits: 0.50
Valid until: 13-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/her2-targeted-adcs-in-advanced-nsclc-a-case-based-approach-to-targeted-treatment-for-metastatic-disease/26285/
The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.
…
continue reading
Valid until: 13-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/her2-targeted-adcs-in-advanced-nsclc-a-case-based-approach-to-targeted-treatment-for-metastatic-disease/26285/
The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.
450 episoder
Manage episode 455848953 series 3128163
Indhold leveret af ReachMD. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af ReachMD eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
CME credits: 0.50
Valid until: 13-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/her2-targeted-adcs-in-advanced-nsclc-a-case-based-approach-to-targeted-treatment-for-metastatic-disease/26285/
The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.
…
continue reading
Valid until: 13-08-2025
Claim your CME credit at https://reachmd.com/programs/cme/her2-targeted-adcs-in-advanced-nsclc-a-case-based-approach-to-targeted-treatment-for-metastatic-disease/26285/
The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.
450 episoder
Alle episoder
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.